Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18545699 | 0.72 | GAA (0.47) | GAAL3MBTL1 | |
| SCHEMBL678213 | 0.71 | GAA (0.44) | GAAL3MBTL1 | |
| SCHEMBL17931191 | 0.70 | GAA (0.54) | GAAL3MBTL1 | |
| SCHEMBL20464752 | 0.69 | GAA (0.42) | GAAL3MBTL1 | |
| SCHEMBL7636857 | 0.69 | GAA (0.58) | GAAL3MBTL1 | |
| SCHEMBL18545631 | 0.69 | GAA (0.58) | GAAL3MBTL1 | |
| SCHEMBL1814713 | 0.69 | GAA (1.00) | GAAL3MBTL1 | |
| SCHEMBL20464751 | 0.68 | GAA (0.47) | GAAL3MBTL1 | |
| SCHEMBL7631741 | 0.68 | GAA (0.47) | GAAL3MBTL1 | |
| SCHEMBL12846238 | 0.68 | GAA (0.52) | GAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202962-A1 | NITROXIDE CONTAINING AMYLOID BINDING AGENTS FOR IMAGING AND THERAPEUTIC USES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-06-30 | — | — | US | disclosed |
| US-20220202800-A1 | Method of Treatment of Organic Acidemias and Other Mitochondria Defects or Deficiencies | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2022-06-30 | — | — | US | disclosed |
| US-10881748-B2 | Nitroxide containing amyloid binding agents for imaging and therapeutic uses | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200246492-A1 | NITROXIDE CONTAINING AMYLOID BINDING AGENTS FOR IMAGING AND THERAPEUTIC USES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-08-06 | — | — | US | disclosed |
| US-10553890-B2 | Aqueous redox flow batteries | UCHICAGO ARGONNE, LLC (US) | 2020-02-04 | — | — | US | disclosed |
| US-10478513-B2 | Nitroxide containing amyloid binding agents for imaging and therapeutic uses | THE REGENTS OF THE UNIVERSITY OF CALIFONIA (US) | 2019-11-19 | — | — | US | disclosed |
| US-20180221514-A1 | NITROXIDE CONTAINING AMYLOID BINDING AGENTS FOR IMAGING AND THERAPEUTIC USES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-08-09 | — | — | US | disclosed |
| US-20180221514-A1 | NITROXIDE CONTAINING AMYLOID BINDING AGENTS FOR IMAGING AND THERAPEUTIC USES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2018-08-09 | — | — | US | disclosed |
| WO-2017031239-A1 | NITROXIDE CONTAINING AMYLOID BINDING AGENTS FOR IMAGING AND THERAPEUTIC USES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-23 | — | — | WO | disclosed |
| US-8846674-B2 | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use | NICOX, S.A. (FR) | 2014-09-30 | — | — | US | disclosed |
| US-20090042819-A1 | Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use | NITROMED, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-20090018091-A1 | Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090012057-A1 | Cardiovascular Compounds Comprising Nitric Oxide Enhancing Groups, Compositions and Methods of Use | NITROMED, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20080306041-A1 | Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use | NICOX S.A. (FR) | 2008-12-11 | — | — | US | disclosed |
| US-20080293678-A1 | Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293702-A1 | Nitric Oxide Enhancing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080268014-A1 | Furoxan Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080255101-A1 | NITRIC OXIDE DONATING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2008-10-16 | — | — | US | disclosed |
| US-7396829-B2 | such as 2H-1,2,4-benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-[5-(nitrooxy)pentyl]-, 1,1-dioxide; contains at least one nitric oxide enhancing group; excessive water or electrolyte retention conditions; cardiovascular diseases, and diseases resulting from oxidative or endothelial dysfunctions | NITROMED, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-20070032533-A1 | Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293702-A1 | Nitric Oxide Enhancing Pyruvate Compounds, Compositions and Methods of Use | PC, PDK1, NOS3 | GAA 2877/4885L3MBTL1 2210/4885 |
| US-20220202962-A1 | NITROXIDE CONTAINING AMYLOID BINDING AGENTS FOR IMAGING AND THERAPEUTIC USES | APP, APBA1, CRYAB | GAA 1175/4885L3MBTL1 3274/4885 |
| US-10881748-B2 | Nitroxide containing amyloid binding agents for imaging and therapeutic uses | APP, APBA1, CRYAB | GAA 1175/4885L3MBTL1 3274/4885 |
| US-10478513-B2 | Nitroxide containing amyloid binding agents for imaging and therapeutic uses | APP, APBA1, CRYAB | GAA 1175/4885L3MBTL1 3274/4885 |
| US-20090012057-A1 | Cardiovascular Compounds Comprising Nitric Oxide Enhancing Groups, Compositions and Methods of Use | REN, EDNRB, ECE1 | GAA 254/4885L3MBTL1 4453/4885 |
| US-20080306041-A1 | Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use | REN, NOX5, NOS3 | GAA 1484/4885L3MBTL1 3468/4885 |
| US-20090018091-A1 | Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use | NOS1, NOS3, NOS2 | GAA 1111/4885L3MBTL1 3869/4885 |
| US-20180221514-A1 | NITROXIDE CONTAINING AMYLOID BINDING AGENTS FOR IMAGING AND THERAPEUTIC USES | APP, APBA1, CRYAB | GAA 1049/4885L3MBTL1 3427/4885 |
| US-20220202800-A1 | Method of Treatment of Organic Acidemias and Other Mitochondria Defects or Deficiencies | OAT, OTC, HOGA1 | GAA 253/4885L3MBTL1 868/4885 |
| US-20200246492-A1 | NITROXIDE CONTAINING AMYLOID BINDING AGENTS FOR IMAGING AND THERAPEUTIC USES | APP, APBA1, CRYAB | GAA 1175/4885L3MBTL1 3274/4885 |
| US-20080268014-A1 | Furoxan Compounds, Compositions and Methods of Use | PTGIS, F3, PTGIR | GAA 4734/4885L3MBTL1 3969/4885 |
| US-20070032533-A1 | Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use | AGTR2, AGTR1, REN | GAA 762/4885L3MBTL1 4289/4885 |
| US-20080293678-A1 | Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use | NOS3, REN, NOS1 | GAA 1190/4885L3MBTL1 3552/4885 |
| US-20080255101-A1 | NITRIC OXIDE DONATING DIURETIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NOS1, NOS3, NOS2 | GAA 1104/4885L3MBTL1 4408/4885 |
| US-20090042819-A1 | Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use | NOS1, NOS2, NOS3 | GAA 1761/4885L3MBTL1 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.